SRR6013484
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.350
- PANCREAS_BETA_CELLS+0.350
- SPERMATOGENESIS+0.290
- TNFA_SIGNALING_VIA_NFKB+0.170
- COAGULATION+0.150
- HYPOXIA+0.150
- HEDGEHOG_SIGNALING+0.120
- MYOGENESIS+0.110
- XENOBIOTIC_METABOLISM+0.110
- ESTROGEN_RESPONSE_LATE+0.100
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.590
- INTERFERON_ALPHA_RESPONSE-0.500
- DNA_REPAIR-0.470
- INTERFERON_GAMMA_RESPONSE-0.420
- ADIPOGENESIS-0.400
- PROTEIN_SECRETION-0.400
- ALLOGRAFT_REJECTION-0.380
- MYC_TARGETS_V1-0.370
- PI3K_AKT_MTOR_SIGNALING-0.360
- NOTCH_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359442 | — | — | 0.895 |
| 2 | MNG835 | — | — | 0.878 |
| 3 | MNG225 | — | — | 0.857 |
| 4 | SRR1797259 | — | cohortSC | 0.855 |
| 5 | SRR1516039 | — | — | 0.846 |
| 6 | 82982 | EPN | Supratentorial EPN | 0.844 |
| 7 | SRR6013476 | — | cohortSQ1 | 0.837 |
| 8 | SRR6013488 | — | cohortA1 | 0.836 |
| 9 | MDT-AP-1190 | Med | Medulloblastoma | 0.834 |
| 10 | MNG370 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |